HHCP
BBIO icon

Hilton Head Capital Partners’s BridgeBio Pharma BBIO Stock Holding History

Hilton Head Capital Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.4K Hold
650
– – 0.02% 335
2026
Q1 		$48.3K Hold
650
– – 0.03% 301
2025
Q4 		$49.7K Buy
+650
New +$42.7K 0.03% 285

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Hilton Head Capital Partners's BBIO Position: Q2 2026 in Review

Hilton Head Capital Partners held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 650 shares worth $48.4K. The position accounts for 0.02% of the portfolio, ranked #335.

Hilton Head Capital Partners first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $49.7K in Q4 2025. 472 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Hilton Head Capital Partners held 650 shares of BridgeBio Pharma worth $48.4K as of Q2 2026.
  • Hilton Head Capital Partners left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.02% of Hilton Head Capital Partners's portfolio in Q2 2026, its #335 holding.
  • Hilton Head Capital Partners first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's BridgeBio Pharma position peaked at $49.7K in Q4 2025.
  • 472 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.